STK17B

Summary

STK17B (serine/threonine kinase 17b, HGNC:11396) is a protein-coding gene on chromosome 2q32.3, encoding Serine/threonine-protein kinase 17B (O94768). Phosphorylates myosin light chains.

Enables ATP binding activity and protein serine/threonine kinase activity. Involved in intracellular signal transduction; positive regulation of fibroblast apoptotic process; and protein phosphorylation. Located in Flemming body and nucleoplasm.

Source: NCBI Gene 9262 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 40 total
• Druggable target: yes — 17 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004226

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11396
Approved symbol	STK17B
Name	serine/threonine kinase 17b
Location	2q32.3
Locus type	gene with protein product
Status	Approved
Aliases	DRAK2
Ensembl gene	ENSG00000081320
Ensembl biotype	protein_coding
OMIM	604727
Entrez	9262

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding, 3 nonsense_mediated_decay

ENST00000263955, ENST00000409228, ENST00000420683, ENST00000449152, ENST00000606789, ENST00000714417, ENST00000714419, ENST00000714420, ENST00000714421, ENST00000714422, ENST00000714423, ENST00000879796, ENST00000879797, ENST00000879798, ENST00000879799, ENST00000915456

RefSeq mRNA: 1 — MANE Select: NM_004226 NM_004226

CCDS: CCDS2315

Canonical transcript exons

ENST00000263955 — 8 exons

Exon	Start	End
ENSE00001159995	196171333	196171578
ENSE00001692887	196163262	196163427
ENSE00004023932	196156439	196156651
ENSE00004023933	196145911	196146055
ENSE00004023934	196133583	196137729
ENSE00004023935	196139620	196139799
ENSE00004023936	196143560	196143686
ENSE00004023937	196141249	196141297

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 98.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 104.4272 / max 5066.3275, expressed in 1816 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
32997	70.1593	1805
32996	28.4180	1658
32995	3.4758	514
32998	2.0968	900
33002	0.1585	82
33001	0.0596	21
32999	0.0553	27
33000	0.0040	1

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelium of nasopharynx	UBERON:0001951	98.32	gold quality
nasopharynx	UBERON:0001728	98.30	gold quality
monocyte	CL:0000576	98.23	gold quality
mononuclear cell	CL:0000842	98.03	gold quality
leukocyte	CL:0000738	97.93	gold quality
jejunal mucosa	UBERON:0000399	97.51	gold quality
calcaneal tendon	UBERON:0003701	96.60	gold quality
tonsil	UBERON:0002372	96.51	gold quality
blood	UBERON:0000178	96.30	gold quality
lymph node	UBERON:0000029	96.22	gold quality
bone marrow	UBERON:0002371	95.80	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.31	gold quality
lower lobe of lung	UBERON:0008949	95.20	gold quality
granulocyte	CL:0000094	94.80	gold quality
colonic epithelium	UBERON:0000397	94.20	gold quality
mammary duct	UBERON:0001765	94.18	gold quality
vermiform appendix	UBERON:0001154	94.13	gold quality
trabecular bone tissue	UBERON:0002483	93.77	gold quality
bone marrow cell	CL:0002092	93.39	gold quality
caecum	UBERON:0001153	93.23	gold quality
adrenal tissue	UBERON:0018303	92.79	gold quality
tibia	UBERON:0000979	92.23	gold quality
amniotic fluid	UBERON:0000173	92.09	gold quality
visceral pleura	UBERON:0002401	91.80	gold quality
spleen	UBERON:0002106	91.74	gold quality
parietal pleura	UBERON:0002400	91.70	gold quality
pleura	UBERON:0000977	91.09	gold quality
epithelium of mammary gland	UBERON:0003244	90.92	gold quality
oral cavity	UBERON:0000167	90.45	gold quality
upper leg skin	UBERON:0004262	90.40	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	188.27
E-MTAB-6701	yes	101.96
E-MTAB-8142	yes	54.30
E-MTAB-10287	yes	37.03
E-MTAB-6678	yes	36.66
E-CURD-122	yes	35.73
E-GEOD-135922	yes	33.13
E-MTAB-9543	yes	18.66
E-CURD-119	yes	5.35
E-MTAB-9067	yes	4.62
E-CURD-112	yes	3.89
E-CURD-10	no	386.94
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYB

miRNA regulators (miRDB)

195 targeting STK17B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642

Literature-anchored findings (GeneRIF, showing 11)

• DRAK2 kinase activity is regulated in a calcium-dependent manner and that Ser(12) phosphorylation is necessary for optimal suppression of T cell activation by this kinase (PMID:17182616)
• Strong suppression of T cell receptor signals during thymic selection caused by ectopic DRAK2 expression in a DRAK2 transgenic mouse model of autoimmune encephalomyelitis alters the responsiveness of peripheral T cells. (PMID:19542440)
• Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer. (PMID:19638987)
• DRAK2 and protein kinase D form a novel signaling module that controls calcium homeostasis following T cell activation. (PMID:21148796)
• DRAK2 protein directly binds to the type I TGF-beta receptor and Knockdown of DRAK2 suppresses the tumorigenic ability of breast cancer cells. (PMID:23122956)
• ChIP assays showed that in U937 cells MYB binds to a conserved element upstream of the DRAK2 transcription start site. (PMID:23398943)
• A significant interaction between variants in STK17B and PAX8, in papillary thyroid cancer susceptibility, is reported. (PMID:24086368)
• STK17B promotes carcinogenesis and metastasis via AKT/GSK-3beta/Snail signaling in hepatocellular carcinoma. (PMID:29445189)
• DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia. (PMID:33081245)
• DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. (PMID:34614409)
• DRAK2 suppresses autophagy by phosphorylating ULK1 at Ser[56] to diminish pancreatic beta cell function upon overnutrition. (PMID:38324636)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	stk17b	ENSDARG00000014348
mus_musculus	Stk17b	ENSMUSG00000026094
rattus_norvegicus	Stk17b	ENSRNOG00000012502
drosophila_melanogaster	Drak	FBGN0052666

Paralogs (1): STK17A (ENSG00000164543)

Protein

Protein identifiers

Serine/threonine-protein kinase 17B — O94768 (reviewed: O94768)

Alternative names: DAP kinase-related apoptosis-inducing protein kinase 2

All UniProt accessions (7): O94768, A0AAQ5BHY2, A0AAQ5BI08, A0AAQ5BI73, C9JZJ1, Q53QE7, U3KQF8

UniProt curated annotations — full annotation on UniProt →

Function. Phosphorylates myosin light chains. Acts as a positive regulator of apoptosis.

Subunit / interactions. Interacts with CHP1; the interaction induces CHP1 to translocate from the Golgi to the nucleus.

Subcellular location. Nucleus. Cell membrane. Endoplasmic reticulum-Golgi intermediate compartment.

Tissue specificity. Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney.

Post-translational modifications. Autophosphorylated.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. DAP kinase subfamily.

RefSeq proteins (1): NP_004217* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR042763	ST17B_STKc	Domain

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (36 total): helix 18, strand 7, turn 2, binding site 2, chain 1, domain 1, region of interest 1, compositionally biased region 1, active site 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
6ZJF	X-RAY DIFFRACTION	1.75
6Y6H	X-RAY DIFFRACTION	1.95
6Y6F	X-RAY DIFFRACTION	1.98
7AKG	X-RAY DIFFRACTION	2.08
3LM5	X-RAY DIFFRACTION	2.29
3LM0	X-RAY DIFFRACTION	2.35
6QF4	X-RAY DIFFRACTION	2.5
7Q7D	X-RAY DIFFRACTION	2.6
7Q7C	X-RAY DIFFRACTION	2.85
7Q7E	X-RAY DIFFRACTION	2.85

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94768-F1	81.31	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 158 (proton acceptor)

Ligand- & substrate-binding residues (2): 39–47; 62

Mutagenesis-validated functional residues (1):

Position	Phenotype
62	loss of activity and of apoptotic function.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 323 (showing top): BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, WALLACE_PROSTATE_CANCER_RACE_UP, TGCACTT_MIR519C_MIR519B_MIR519A, ENK_UV_RESPONSE_KERATINOCYTE_UP, TTTGTAG_MIR520D, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GRANDVAUX_IRF3_TARGETS_DN, RODRIGUES_NTN1_TARGETS_DN, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, FINETTI_BREAST_CANCER_KINOME_GREEN, FISCHER_G2_M_CELL_CYCLE, MODULE_206

GO Biological Process (7): protein phosphorylation (GO:0006468), apoptotic process (GO:0006915), intracellular signal transduction (GO:0035556), positive regulation of apoptotic process (GO:0043065), protein autophosphorylation (GO:0046777), positive regulation of fibroblast apoptotic process (GO:2000271), programmed cell death (GO:0012501)

GO Molecular Function (7): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), endoplasmic reticulum-Golgi intermediate compartment (GO:0005793), plasma membrane (GO:0005886), actin cytoskeleton (GO:0015629), Flemming body (GO:0090543), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
signal transduction	2
protein kinase activity	2
intracellular membrane-bounded organelle	2
phosphorylation	1
protein modification process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
intracellular anatomical structure	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
protein phosphorylation	1
positive regulation of apoptotic process	1
fibroblast apoptotic process	1
regulation of fibroblast apoptotic process	1
cell death	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
cytoskeleton	1
midbody	1

Protein interactions and networks

STRING

1717 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STK17B	DAP	P51397	581
STK17B	CHP1	Q99653	567
STK17B	PRKD3	O94806	453
STK17B	PRKD2	Q9BZL6	452
STK17B	PRKD1	Q15139	451
STK17B	HECW2	Q9P2P5	437
STK17B	PLEKHF1	Q96S99	428
STK17B	SPRR2G	Q9BYE4	414
STK17B	RMP24	Q32NC0	409
STK17B	NME5	P56597	401
STK17B	CDC7	O00311	393
STK17B	NUP35	Q8NFH5	389
STK17B	DRC11	Q86XH1	387
STK17B	ITPR1	Q14643	383
STK17B	TMEM101	Q96IK0	359

IntAct

37 interactions, top by confidence:

A	B	Type	Score
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
LAMP1	FZD7	psi-mi:“MI:0914”(association)	0.530
STK17B	KCNIP2	psi-mi:“MI:0915”(physical association)	0.400
STK17B	UBA52	psi-mi:“MI:0915”(physical association)	0.400
STK17B	RPS24	psi-mi:“MI:0915”(physical association)	0.370
STK17B	SCAMP3	psi-mi:“MI:0914”(association)	0.350
STK17B	REV3L	psi-mi:“MI:0914”(association)	0.350
TMEM30A	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
P2RX5	NOP56	psi-mi:“MI:0914”(association)	0.350
CHRM4	GEMIN2	psi-mi:“MI:0914”(association)	0.350
LPAR6	DEGS1	psi-mi:“MI:0914”(association)	0.350
LAMP1	ORC4	psi-mi:“MI:0914”(association)	0.350
CHSY3	STK17B	psi-mi:“MI:0914”(association)	0.350
STK17B	TPM2	psi-mi:“MI:0914”(association)	0.350
STK17B	H2AZ1	psi-mi:“MI:0914”(association)	0.350
IGHM	ESYT2	psi-mi:“MI:0914”(association)	0.350
AVPR2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
HCST	TMEM120B	psi-mi:“MI:0914”(association)	0.350
HIDE1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
MLNR	NBAS	psi-mi:“MI:0914”(association)	0.350
CD80	POTEF	psi-mi:“MI:0914”(association)	0.350
TACSTD2	RIMOC1	psi-mi:“MI:0914”(association)	0.350
FAXC	METTL15	psi-mi:“MI:0914”(association)	0.350
FPR1	GPR89A	psi-mi:“MI:0914”(association)	0.350
P2RX5	TNPO2	psi-mi:“MI:0914”(association)	0.350
CHRM4	TNPO2	psi-mi:“MI:0914”(association)	0.350
COMTD1	TARS3	psi-mi:“MI:0914”(association)	0.350

BioGRID (68): STK17B (Affinity Capture-MS), STK17B (Affinity Capture-MS), AFMID (Affinity Capture-MS), KCNIP2 (Affinity Capture-MS), REV3L (Affinity Capture-MS), SLC2A1 (Affinity Capture-MS), TOX4 (Affinity Capture-MS), SCAMP3 (Affinity Capture-MS), TRIB1 (Affinity Capture-MS), ATXN2L (Affinity Capture-MS), MDN1 (Affinity Capture-MS), FAF2 (Affinity Capture-MS), WBP11 (Affinity Capture-MS), UBAC2 (Affinity Capture-MS), STK17B (Affinity Capture-MS)

ESM2 similar proteins: D4A7V9, F1QGZ6, O15530, O54785, O54863, O94768, O96017, P53351, P53666, P53670, P53671, P92958, Q14680, Q20443, Q28GW8, Q32L23, Q38997, Q3SZW1, Q5HZ38, Q5RBJ6, Q5SUV5, Q61241, Q61846, Q6DE87, Q6SA08, Q7RTN6, Q7TNJ7, Q7TNZ6, Q852Q2, Q86YV6, Q8BG48, Q8C1R0, Q8NG66, Q8VDF3, Q8WNU8, Q91821, Q91VB2, Q91XS8, Q93V58, Q96NX5

Diamond homologs: A0A509AFG4, A0A5K1K8H0, A2AAJ9, A2ZVI7, A4IFM7, A8C984, A8WXF6, B9FKW9, C0HKC8, C0HKC9, E9PT87, O02827, O43293, O44997, O54784, O62305, O70150, O75147, O80673, O88764, O94768, P07313, P08414, P11801, P13234, P15735, P18653, P20689, P29294, P31325, P34101, P43292, P53355, P53681, Q00168, Q00771, Q0KHT7, Q0V7M1, Q10KY3, Q14012

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PRKD1	“up-regulates activity”	STK17B	phosphorylation
PRKCG	“down-regulates activity”	STK17B	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1628 predictions. Top by Δscore:

Variant	Effect	Δscore
2:196139614:A:AC	donor_gain	1.0000
2:196139615:C:CC	donor_gain	1.0000
2:196139615:CTTA:C	donor_gain	1.0000
2:196139616:TTAC:T	donor_loss	1.0000
2:196139617:TACTC:T	donor_loss	1.0000
2:196139618:A:AC	donor_gain	1.0000
2:196139618:A:T	donor_loss	1.0000
2:196139618:ACT:A	donor_gain	1.0000
2:196139619:C:CC	donor_gain	1.0000
2:196139619:CT:C	donor_gain	1.0000
2:196139619:CTC:C	donor_gain	1.0000
2:196139619:CTCT:C	donor_gain	1.0000
2:196139619:CTCTG:C	donor_gain	1.0000
2:196139795:TATTC:T	acceptor_gain	1.0000
2:196139797:TTC:T	acceptor_gain	1.0000
2:196139798:TC:T	acceptor_gain	1.0000
2:196139799:CC:C	acceptor_gain	1.0000
2:196139800:C:CA	acceptor_loss	1.0000
2:196139800:C:CC	acceptor_gain	1.0000
2:196139801:T:C	acceptor_loss	1.0000
2:196141248:CCA:C	donor_gain	1.0000
2:196141255:T:C	donor_gain	1.0000
2:196141297:GC:G	acceptor_loss	1.0000
2:196141298:C:CA	acceptor_loss	1.0000
2:196141298:C:CC	acceptor_gain	1.0000
2:196141299:T:A	acceptor_loss	1.0000
2:196143554:TCTTA:T	donor_loss	1.0000
2:196143555:CTTA:C	donor_loss	1.0000
2:196143556:TTAC:T	donor_loss	1.0000
2:196143557:TACC:T	donor_loss	1.0000

AlphaMissense

2453 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:196137723:T:A	R281S	0.999
2:196137723:T:G	R281S	0.999
2:196137724:C:G	R281T	0.999
2:196139791:C:T	G222D	0.999
2:196139792:C:G	G222R	0.999
2:196141250:A:G	W219R	0.999
2:196141250:A:T	W219R	0.999
2:196143630:A:C	D179E	0.999
2:196143630:A:T	D179E	0.999
2:196143631:T:A	D179V	0.999
2:196156588:T:A	K62N	0.999
2:196156588:T:G	K62N	0.999
2:196156595:G:T	A60D	0.999
2:196139751:A:C	F235L	0.998
2:196139751:A:T	F235L	0.998
2:196139753:A:G	F235L	0.998
2:196139791:C:A	G222V	0.998
2:196139799:C:A	W219C	0.998
2:196139799:C:G	W219C	0.998
2:196143631:T:G	D179A	0.998
2:196143632:C:G	D179H	0.998
2:196145918:T:A	D158V	0.998
2:196145958:C:G	G145R	0.998
2:196145958:C:T	G145R	0.998
2:196156523:A:G	L84P	0.998
2:196156590:T:C	K62E	0.998
2:196156590:T:G	K62Q	0.998
2:196156592:G:T	A61E	0.998
2:196156593:C:G	A61P	0.998
2:196156624:A:C	C50W	0.998

dbSNP variants (sampled 300 via entrez): RS1000012000 (2:196141128 T>C), RS1000074930 (2:196169305 T>C), RS1000085688 (2:196162560 A>G), RS1000122190 (2:196169604 T>C), RS1000151141 (2:196177190 C>T), RS1000221199 (2:196162852 T>C,G), RS1000388486 (2:196157270 A>G), RS1000445284 (2:196151439 G>A), RS1000480932 (2:196134649 G>A), RS1000497218 (2:196151631 T>A), RS1000539371 (2:196139305 T>C), RS1000639401 (2:196147619 A>G), RS1000642993 (2:196145589 A>G), RS1000659767 (2:196138719 G>A), RS1000795301 (2:196138935 A>G)

Disease associations

OMIM: gene MIM:604727 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST90002381_55	Eosinophil count	9.000000e-11
GCST90002382_81	Eosinophil percentage of white cells	3.000000e-12
GCST90002396_178	Mean reticulocyte volume	1.000000e-09
GCST90002397_455	Mean spheric corpuscular volume	3.000000e-14

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0007991	eosinophil percentage of leukocytes
EFO:0010701	mean reticulocyte volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3980 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

17 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 396,768 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL180022	NERATINIB	4	9,404
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL939	GEFITINIB	4	117,814
CHEMBL31965	CANERTINIB	3	8,083
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1721885	SU-014813	2	363
CHEMBL475251	R-406	2	762
CHEMBL607707	PELITINIB	2	6,340
CHEMBL1908397	KW-2449	1	622
CHEMBL259084	MLN-8054	1	2,430

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Death-associated kinase (DAPK) family

Binding affinities (BindingDB)

9 measured of 10 human assays (10 total across all organisms); most potent 9 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
4-[[7-[2,6-bis(fluoranyl)phenyl]-9-chloranyl-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid	KD	300 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
GEFITINIB	IC50	2300 nM	US-9416123: Kinase modulators for the treatment of cancer
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
(E)-N-[4-(3-chloro-4-fluoro-anilino)-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide	KD	3500 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S)-3-hydroxy-1-methyl-4-piperidinyl]-1-benzopyran-4-one	KD	5300 nM

ChEMBL bioactivities

216 potent at pChembl≥5 of 235 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.59	Ki	0.26	nM	CHEMBL3797480
8.52	IC50	3	nM	CHEMBL3797480
8.42	Kd	3.8	nM	CHEMBL1836719
8.32	Kd	4.8	nM	KW-2449
8.30	Kd	5	nM	LESTAURTINIB
8.25	Kd	5.6	nM	CHEMBL4752776
8.15	IC50	7	nM	CHEMBL4796519
8.10	IC50	8	nM	CHEMBL3799389
8.10	Kd	8	nM	CHEMBL4060481
8.09	Kd	8.1	nM	MLN-8054
8.05	Kd	9	nM	CHEMBL3334979
8.04	Kd	9.2	nM	R-406
8.00	IC50	10	nM	CHEMBL3799585
8.00	IC50	10	nM	CHEMBL5433785
7.96	Kd	11	nM	CHEMBL1836721
7.89	IC50	13	nM	CHEMBL4760126
7.85	IC50	14	nM	CHEMBL3797466
7.85	IC50	14	nM	CHEMBL3799505
7.85	IC50	14	nM	CHEMBL4753926
7.75	IC50	18	nM	CHEMBL4763132
7.70	IC50	20	nM	CHEMBL1836719
7.68	IC50	21	nM	CHEMBL513703
7.68	Kd	21	nM	STAUROSPORINE
7.64	IC50	23	nM	CHEMBL1836724
7.59	IC50	25.8	nM	STAUROSPORINE
7.58	Kd	26	nM	STAUROSPORINE
7.57	Kd	27	nM	CHEMBL3334980
7.57	IC50	27	nM	CHEMBL4754748
7.55	IC50	28	nM	CHEMBL4794509
7.54	IC50	29	nM	CHEMBL4060481
7.52	Kd	30	nM	CHEMBL1836641
7.52	IC50	30	nM	CHEMBL6005757
7.48	Kd	33	nM	CHEMBL3334981
7.48	IC50	33	nM	CHEMBL4788024
7.47	IC50	34	nM	CHEMBL4752776
7.46	IC50	35	nM	CHEMBL1836717
7.46	IC50	35	nM	CHEMBL4747753
7.43	IC50	37	nM	CHEMBL4740090
7.41	IC50	39	nM	CHEMBL1836714
7.40	IC50	40	nM	CHEMBL4783516
7.40	IC50	40	nM	CHEMBL5831473
7.39	IC50	41	nM	CHEMBL4753625
7.35	Kd	45	nM	FEDRATINIB
7.31	IC50	49	nM	CHEMBL4745018
7.31	IC50	49	nM	CHEMBL4740604
7.31	IC50	49	nM	CHEMBL4789685
7.23	IC50	59	nM	CHEMBL4748440
7.22	IC50	60	nM	CHEMBL4788886
7.21	IC50	62	nM	CHEMBL4739879
7.20	IC50	63	nM	CHEMBL4792541

PubChem BioAssay actives

188 with measured affinity, of 655 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]pentanamide	1298205: Competitive inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by Lineweaver-Burk plot analysis in presence of ATP	ki	0.0003	uM
2-[6-(4-methylsulfanylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718368: Binding affinity to N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli by KINOMEscan scanMAX assay	kd	0.0038	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624942: Binding constant for DRAK2 kinase domain	kd	0.0048	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507904: Binding affinity to DRAK2	kd	0.0050	uM
2-[6-(1-benzothiophen-2-yl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718368: Binding affinity to N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli by KINOMEscan scanMAX assay	kd	0.0056	uM
2-[6-(4-methylsulfinylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0070	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]cyclopropanecarboxamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0080	uM
5-(3-amino-5-thiophen-3-ylthieno[2,3-b]pyridin-2-yl)-3H-1,3,4-oxadiazole-2-thione	1966671: Binding affinity to DRAK2 (unknown origin) assessed as dissociation constant	kd	0.0080	uM
4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid	435401: Binding constant for full-length DRAK2	kd	0.0081	uM
N-[5-(3,4-dimethoxyphenyl)thieno[2,3-b]pyridin-3-yl]cyclohexanecarboxamide	1162292: Binding affinity to DRAK2 (unknown origin) ATP site	kd	0.0090	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624942: Binding constant for DRAK2 kinase domain	kd	0.0092	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]butanamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0100	uM
4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methoxy-2-N-[4-(methylsulfonylmethyl)phenyl]pyrimidine-2,4-diamine	1966670: Inhibition of DRAK2 (unknown origin)	ic50	0.0100	uM
2-[6-(4-carbamoylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718368: Binding affinity to N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli by KINOMEscan scanMAX assay	kd	0.0110	uM
2-[6-(4-acetylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0130	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-3-methylbut-2-enamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0140	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-3,3-dimethylbutanamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0140	uM
2-[6-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0140	uM
2-[6-(3-fluoro-4-methoxyphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0180	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-2,2-dimethylpropanamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0210	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	435401: Binding constant for full-length DRAK2	kd	0.0210	uM
2-[6-(4-acetamidophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0230	uM
N-[2-(3,4-dimethoxyphenyl)thieno[2,3-b]pyrazin-7-yl]cyclohexanecarboxamide	1162292: Binding affinity to DRAK2 (unknown origin) ATP site	kd	0.0270	uM
2-[6-(3-fluoro-4-methylsulfanylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0270	uM
2-[6-(4-ethenylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0280	uM
2-[6-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-yl]oxyacetic acid	1718368: Binding affinity to N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli by KINOMEscan scanMAX assay	kd	0.0300	uM
N-[5-(3,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]cyclohexanecarboxamide	1162292: Binding affinity to DRAK2 (unknown origin) ATP site	kd	0.0330	uM
2-[6-[4-(trifluoromethyl)phenyl]thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0330	uM
2-[6-(3-acetamidophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0350	uM
2-[6-(4-cyanophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0350	uM
2-[6-(6-acetyl-3-pyridinyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0370	uM
2-[6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0390	uM
2-[6-(4-ethoxycarbonylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0400	uM
2-[6-(4-ethylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0410	uM
Fedratinib	624942: Binding constant for DRAK2 kinase domain	kd	0.0450	uM
2-[6-(4-propan-2-ylsulfanylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0490	uM
2-[6-(3-fluorophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0490	uM
2-[6-(3-methylsulfanylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0490	uM
2-[6-(4-propan-2-ylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0590	uM
2-[6-(2-fluorophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0600	uM
2-[6-(4-cyclopropylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0620	uM
2-(6-thiophen-2-ylthieno[3,2-d]pyrimidin-4-yl)sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0630	uM
2-[6-(3,4-difluorophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0740	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]-3,5-dinitrobenzamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.0770	uM
2-[6-(3-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0830	uM
2-[6-(3,4-dichlorophenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.0920	uM
2-[6-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.1100	uM
2-[6-(4-phenylmethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl]sulfanylacetic acid	1718373: Inhibition of N-terminal His-tagged STK17B kinase domain (25 to 329 residues) (unknown origin) expressed in Escherichia coli incubated for 90 mins by Kinase seeker split luciferase assay	ic50	0.1100	uM
Sunitinib	435401: Binding constant for full-length DRAK2	kd	0.1100	uM
N-[2-hydroxy-3-(3-nitroso-1H-indol-2-yl)-1H-indol-5-yl]cyclohexanecarboxamide	1298193: Inhibition of DRAK2 (unknown origin) using MRLC3 peptide as substrate incubated for 2 hrs by ADP-Glo kinase assay	ic50	0.1200	uM

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	affects expression, affects methylation	2
Dexamethasone	increases expression, affects cotreatment	2
Nickel	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
TL8-506	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	affects expression	1
butyraldehyde	increases expression	1
sulindac sulfide	increases expression	1
benzo(e)pyrene	increases methylation	1
resorcinol	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	decreases expression	1
Decitabine	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects cotreatment, decreases expression	1
Fulvestrant	increases methylation	1
Vorinostat	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ascorbic Acid	affects cotreatment, increases expression	1

ChEMBL screening assays

179 unique, capped per target: 179 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1034105	Binding	Inhibition of DRAK2 at 3 uM	Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1QT	Abcam K-562 STK17B KO	Cancer cell line	Female
CVCL_D2ME	Abcam Raji STK17B KO	Cancer cell line	Male
CVCL_TQ76	HAP1 STK17B (-) 1	Cancer cell line	Male
CVCL_TQ77	HAP1 STK17B (-) 2	Cancer cell line	Male
CVCL_WQ62	Abcam Jurkat STK17B KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.